This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.


This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Medical University of Graz, Graz, Austria

Dr. Thomas Pieber is Professor of Medicine, Chair of the Division of Endocrinology and Diabetology at the Department of Internal Medicine at Medical University of Graz in Austria. He is also Director of the Institute of Biomedicine and Health Sciences at Joanneum Research in Graz and founder of CBmed, a competence centre for biomarker research. Dr. Thomas Pieber and his group have developed and tested several new therapeutic concepts for the type1 and type 2 diabetes, from new pharmacological interventions to innovative medical devices; and from strategies for disease prevention to research in the field of integrative care and outcome research. Dr. Thomas Pieber was and currently is principal investigator (PI) in several international study groups and multicenter trials funded by the EU Commission and foundations such as JDRF and LRA in the USA. In basic research he and his team investigate the role of metabolism in aging and ß-cell resilience.

Dr. Thomas Pieber has written more than 450 original papers and reviews in peer-reviewed journals. He is a member of the International Working Group on the Diabetic Foot and a member of the Cochrane Review Group “Endocrine and Metabolic Diseases”. Furthermore, he serves as reviewer or advisor for international journals and funding organizations.

Thomas Danne

Thomas Danne

Hannover Medical School, Hannover, Germany

Dr. Thomas Danne is the Director of the Department of General Pediatrics Endocrinology/Diabetology & Clinical Research at the “AUF DER BULT” Hospital for Children and Adolescents, Hannover Medical School, Germany, which is the largest pediatric diabetes center in Germany. He trained at the Free University Berlin Children´s Hospital in Berlin and was Consultant Pediatrician at the Charité Children´s Hospital of the Humboldt University Berlin. He is a former Research Fellow of the Joslin Diabetes Center of Harvard Medical School in Boston. Presently he is appointed as Chairman of the SWEET-registry ( and work-package leader of the INNODIA-project (, a consortium to fight type 1 diabetes. He has served as Secretary-General of the International Society for Pediatric and Adolescent Diabetes (ISPAD) from 2004 – 2008 and as President 2008-2010. Also, he is the Past-President of the German Diabetes Association (DDG) and the German Diabetes Aid (diabetesDE). He has been awarded the “Helmut-Otto-Medal” of the German Diabetes Association, the “Somogyi-Award” of the Hungarian Diabetes Association the ISPAD “Prize of Achievement” and the “Lifetime Achievement Award” of the International Diabetes Federation (IDF). His research interests include basic and clinical research in pediatric diabetology with special emphasis on quality improvement through registers, new insulins, glucose sensors, insulin pumps and automated insulin delivery.

Read full bio